MX2015013401A - Procedimiento de tratamiento. - Google Patents
Procedimiento de tratamiento.Info
- Publication number
- MX2015013401A MX2015013401A MX2015013401A MX2015013401A MX2015013401A MX 2015013401 A MX2015013401 A MX 2015013401A MX 2015013401 A MX2015013401 A MX 2015013401A MX 2015013401 A MX2015013401 A MX 2015013401A MX 2015013401 A MX2015013401 A MX 2015013401A
- Authority
- MX
- Mexico
- Prior art keywords
- saccharide
- meningitidis
- capsular
- immunising
- meningitidis serogroup
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 abstract 8
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 3
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 229940031670 conjugate vaccine Drugs 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 208000034762 Meningococcal Infections Diseases 0.000 abstract 1
- 241001174901 Neisseria meningitidis alpha275 Species 0.000 abstract 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 abstract 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 abstract 1
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Virology (AREA)
Abstract
La solicitud divulga un procedimiento de inmunización frente a la infección por Neisseria meningitidis, el cual comprende las etapas de a) inmunizar a un paciente humano a una primera edad de entre 0 y 11 meses con una vacuna conjugada de sacáridos bacterianos que comprende al menos uno, dos o tres sacáridos bacterianos conjugados por separado con una proteína transportadora para formar al menos uno, dos o tres conjugados de sacáridos bacterianos; y b) inmunizar al paciente humano a una segunda edad de entre 12 y 24 meses con una vacuna conjugada contra Neisseria meningitidis que comprende al menos dos sacáridos capsulares seleccionados del grupo constituido por el sacárido capsular del serogrupo A de N. meningitidis (MenA), el sacárido capsular del serogrupo C de N. meningitidis (MenG), el sacárido capsular del serogrupo W135 de N. meningitidis (MenW135) y el sacárido capsular del serogrupo Y de N. meningitidis (MenY) conjugados por separado con una proteína transportadora, en donde la vacuna conjugada contra Neisseria meningitidis se coadministra con una vacuna que comprende el toxoide diftérico y el toxoide tetánico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361802918P | 2013-03-18 | 2013-03-18 | |
| US201361874008P | 2013-09-05 | 2013-09-05 | |
| PCT/EP2014/055355 WO2014147044A1 (en) | 2013-03-18 | 2014-03-17 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013401A true MX2015013401A (es) | 2016-01-08 |
Family
ID=50336313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013401A MX2015013401A (es) | 2013-03-18 | 2014-03-17 | Procedimiento de tratamiento. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11883478B2 (es) |
| EP (1) | EP2976101B1 (es) |
| JP (2) | JP6747968B2 (es) |
| KR (1) | KR20150121265A (es) |
| CN (1) | CN105188743A (es) |
| AU (1) | AU2014234408B2 (es) |
| BE (1) | BE1021934B1 (es) |
| BR (1) | BR112015024014A2 (es) |
| CA (1) | CA2903322C (es) |
| CY (1) | CY1123600T1 (es) |
| DK (1) | DK2976101T3 (es) |
| EA (1) | EA034380B1 (es) |
| ES (1) | ES2830035T3 (es) |
| HU (1) | HUE051592T2 (es) |
| IL (1) | IL241096B (es) |
| MX (1) | MX2015013401A (es) |
| PL (1) | PL2976101T3 (es) |
| PT (1) | PT2976101T (es) |
| SG (2) | SG10201710137QA (es) |
| SI (1) | SI2976101T1 (es) |
| WO (1) | WO2014147044A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190044663A (ko) | 2016-09-02 | 2019-04-30 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| EP3706787A4 (en) * | 2017-11-06 | 2021-10-20 | OZQ Pty Ltd | VACCINE |
| CN110652585B (zh) * | 2018-10-26 | 2023-05-26 | 武汉博沃生物科技有限公司 | 多糖-蛋白缀合物免疫制剂及其制备与应用 |
| MX2022006054A (es) * | 2019-11-22 | 2022-06-24 | Glaxosmithkline Biologicals Sa | Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| GEP20053691B (en) * | 2001-01-23 | 2005-12-12 | Pasteur | Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| AU2012203419B2 (en) | 2005-06-27 | 2014-06-26 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| KR101351870B1 (ko) * | 2005-06-27 | 2014-02-17 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| BRPI0620418A2 (pt) * | 2005-12-23 | 2011-11-08 | Glaxosmithkline Biolog Sa | método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit |
| AU2007229449A1 (en) | 2006-03-22 | 2007-10-04 | Novartis Ag | Regimens for immunisation with meningococcal conjugates |
-
2014
- 2014-03-17 AU AU2014234408A patent/AU2014234408B2/en active Active
- 2014-03-17 BE BE2014/0175A patent/BE1021934B1/fr active
- 2014-03-17 EA EA201591468A patent/EA034380B1/ru not_active IP Right Cessation
- 2014-03-17 KR KR1020157030027A patent/KR20150121265A/ko not_active IP Right Cessation
- 2014-03-17 US US14/777,985 patent/US11883478B2/en active Active
- 2014-03-17 PL PL14711232T patent/PL2976101T3/pl unknown
- 2014-03-17 EP EP14711232.0A patent/EP2976101B1/en not_active Revoked
- 2014-03-17 PT PT147112320T patent/PT2976101T/pt unknown
- 2014-03-17 WO PCT/EP2014/055355 patent/WO2014147044A1/en active Application Filing
- 2014-03-17 SI SI201431706T patent/SI2976101T1/sl unknown
- 2014-03-17 BR BR112015024014A patent/BR112015024014A2/pt not_active Application Discontinuation
- 2014-03-17 ES ES14711232T patent/ES2830035T3/es active Active
- 2014-03-17 CN CN201480016792.XA patent/CN105188743A/zh active Pending
- 2014-03-17 MX MX2015013401A patent/MX2015013401A/es unknown
- 2014-03-17 SG SG10201710137QA patent/SG10201710137QA/en unknown
- 2014-03-17 JP JP2016503631A patent/JP6747968B2/ja active Active
- 2014-03-17 DK DK14711232.0T patent/DK2976101T3/da active
- 2014-03-17 CA CA2903322A patent/CA2903322C/en active Active
- 2014-03-17 SG SG11201506810RA patent/SG11201506810RA/en unknown
- 2014-03-17 HU HUE14711232A patent/HUE051592T2/hu unknown
-
2015
- 2015-09-03 IL IL241096A patent/IL241096B/en active IP Right Grant
-
2019
- 2019-04-04 JP JP2019072050A patent/JP2019142898A/ja active Pending
-
2020
- 2020-11-19 CY CY20201101097T patent/CY1123600T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL241096B (en) | 2021-05-31 |
| CN105188743A (zh) | 2015-12-23 |
| JP2019142898A (ja) | 2019-08-29 |
| PT2976101T (pt) | 2020-11-12 |
| US20160279225A1 (en) | 2016-09-29 |
| CA2903322C (en) | 2023-09-05 |
| HUE051592T2 (hu) | 2021-03-01 |
| SG10201710137QA (en) | 2018-01-30 |
| IL241096A0 (en) | 2015-11-30 |
| JP2016515539A (ja) | 2016-05-30 |
| SG11201506810RA (en) | 2015-10-29 |
| US11883478B2 (en) | 2024-01-30 |
| PL2976101T3 (pl) | 2021-03-08 |
| AU2014234408A1 (en) | 2015-10-22 |
| EA201591468A1 (ru) | 2016-04-29 |
| EP2976101B1 (en) | 2020-08-19 |
| CY1123600T1 (el) | 2022-03-24 |
| SI2976101T1 (sl) | 2021-01-29 |
| EP2976101A1 (en) | 2016-01-27 |
| AU2014234408B2 (en) | 2017-04-20 |
| BE1021934B1 (fr) | 2016-01-27 |
| EA034380B1 (ru) | 2020-01-31 |
| WO2014147044A1 (en) | 2014-09-25 |
| KR20150121265A (ko) | 2015-10-28 |
| CA2903322A1 (en) | 2014-09-25 |
| ES2830035T3 (es) | 2021-06-02 |
| JP6747968B2 (ja) | 2020-08-26 |
| DK2976101T3 (da) | 2020-11-23 |
| BR112015024014A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126443A2 (es) | Composiciones inmunugéincas multivalentes que comprenden 21 conjugados de polisacárido de streptococcus pneumoniae con proteína portadora | |
| GB201101665D0 (en) | Immunogenic compositions | |
| PH12017501898A1 (en) | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | |
| NZ598367A (en) | Multiple vaccination including serogroup C meningococcus | |
| PH12021551448A1 (en) | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof | |
| CR10123A (es) | Vacuna. | |
| ATE463261T1 (de) | Meningokokken-konjugat-impfung | |
| CY1123600T1 (el) | Μεθοδος θεραπειας | |
| BRPI0607374B8 (pt) | vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis | |
| BRPI0818545A2 (pt) | formulações de vacinais meningocócicas | |
| PH12014501887A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| MX2015002483A (es) | Composiciones inmunogenicas. | |
| BRPI0411875A (pt) | método de imunização contra os sorogrupos a e c de neisseria meningitidis | |
| WO2018042017A3 (en) | Vaccines for neisseria gonorrhoeae | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| AR095579A1 (es) | Procedimiento de inmunización | |
| MX2007007790A (es) | Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente. | |
| MX2013002841A (es) | Composiciones inmunogenas. |